Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

OBJECTIVES: Compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic thromboembolism (STE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban or other oral anticoagulants (OACs). METHODS: We performed a retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Belhassen, Manon, Hanon, Olivier, Steg, Philippe Gabriel, Mahé, Isabelle, Née, Mélanie, Jacoud, Flore, Dalon, Faustine, Cotté, François-Emery, Guitard-Dehoux, Dominique, Marant-Micallef, Claire, Van Ganse, Eric, Danchin, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290596/
https://www.ncbi.nlm.nih.gov/pubmed/36030485
http://dx.doi.org/10.1007/s10198-022-01513-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290596/
https://www.ncbi.nlm.nih.gov/pubmed/36030485
http://dx.doi.org/10.1007/s10198-022-01513-2

Ejemplares similares